CA thumbs down Sanofi’s appeal on Dengvaxia

MANILA, Philippines — French pharmaceutical giant Sanofi Pasteur’s motion for reconsideration on a ruling related to its controversial Dengvaxia dengue vaccine has been denied by the Court of Appeals (CA).

In 2018, the Philippine government revoked the certificates of product registration (CPRs) of Sanofi’s Dengvaxia.

Sanofi disclosed in 2017 that Dengvaxia posed risks to people who had not been infected by the virus, prompting the government to halt its nationwide dengue vaccination program launched in 2016.

In a two-page resolution dated Sept. 20, the appellate court upheld its Jan. 31 decision dismissing Sanofi’s petition for review, which challenged the government’s permanent revocation of Dengvaxia’s CPRs.

“A motion for reconsideration grounded on arguments already submitted to this Court and found to be without merit may be denied summarily, as it would be a useless ritual for this Court to reiterate itself,” Associate Justice Eduardo Ramos Jr. said.

The revocation of Dengvaxia’s CPRs remains in place.